Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IIIB Non-small Cell Lung Cancer: early-phase trial registry
A small indexed set (17 trials) with no open enrollment listed right now.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · none currently recruiting · #1,004 of 28,707 conditions by registered trial count
Stage IIIB Non-small Cell Lung Cancer: 17 US clinical trials tracked, none currently recruiting.
Stage IIIB Non-small Cell Lung Cancer is the subject of 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 9 of these trials.
Enrollment posture brief
Registry condition stage-iiib-non-small-cell-lung-cancer
OPEN 0 | RECR 0% | LATE 0 | EARLY 15 | RANK #1004 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Stage IIIB Non-small Cell Lung Cancer has no open enrollment in this registry pull (17 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IIIB Non-small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IIIB Non-small Cell Lung Cancer is recruiting below its size-band peers.
0 of 17 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IIIB Non-small Cell Lung Cancer research.
National Cancer Institute (NCI) accounts for 9 of 17 trials (52.9%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IIIB Non-small Cell Lung Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 17 trials that report a genuine target (sentinel values excluded). 16 of those (94.1%) plan for fewer than 100 participants.
-
Stage IIIB Non-small Cell Lung Cancer research is mostly interventional.
17 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
17 total, page 1 of 1
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Alliance Foundation Trials
NCT04062708
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Jonsson Comprehensive Cancer Center
NCT01345851
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00085280
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00387465
Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00062101
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00087412
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
Susanne Arnold
NCT00247416
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00079235
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00055757
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
Wake Forest University Health Sciences
NCT02581943
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
National Cancer Institute (NCI)
NCT00118144
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00052338
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
NCT02621398
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00778167
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
Roswell Park Cancer Institute
NCT01781741
Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
Shionogi
NCT00078390
18F-FSPG PET/CT for Cancer Patients on Therapy
Andrei Iagaru
NCT02599194
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IIIB Non-small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IIIB Non-small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IIIB Non-small Cell Lung Cancer page
17 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Stage IIIB Non-small Cell Lung Cancer trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Stage IIIB Non-small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIIB Non-small Cell Lung Cancer condition card totals 17 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.